Silexion Therapeutics to Showcase Innovations at Conference
Silexion Therapeutics Corp. (NASDAQ: SLXN), a cutting-edge biotechnology firm specializing in RNA interference (RNAi) therapies for KRAS-driven cancers, is set to make a significant impact at the upcoming 27th Annual H.C. Wainwright Global Investment Conference. This prestigious event is scheduled to take place from September 8 to September 10 at the elegant Lotte New York Palace Hotel. This opportunity highlights Silexion's commitment to advancing oncology treatments and fostering investor relationships.
Company Presentation Details
During the conference, Silexion's senior management will deliver a presentation on September 10 at 2:00 PM ET. Attendees can expect insight into Silexion’s latest developments and research findings. An updated company presentation has already been made accessible on the investor relations section of Silexion's website. This transparency underscores the company’s dedication to keeping investors informed and engaged with their progress.
Opportunities for Direct Engagement
To maximize investor interactions, Silexion's management team will also be available for one-on-one meetings during the conference. Investors keen on discussing personalized insights can request these meetings through their H.C. Wainwright representative, ensuring an efficient and beneficial experience for all stakeholders involved.
Focused on KRAS-Driven Cancers
Silexion Therapeutics stands out in the biotechnology sector, primarily focusing on RNAi therapies designed to target solid tumor cancers featuring the KRAS oncogene. This gene is known as a predominant oncogenic driver across numerous human cancers, making Silexion's research vital in the ongoing battle against cancer treatment inadequacies. Their pioneering efforts aim to develop innovative therapies that address critical gaps in existing cancer treatments.
Clinical Advancements and Commitment
The company has made headway with their first-generation product, which has entered Phase 2a clinical trials. Preliminary results suggest a promising trend showing efficacy against traditional chemotherapy. The aim is to refine these therapies further, especially for conditions like locally advanced pancreatic cancer. Such advancements reinforce Silexion’s commitment to enhancing patient outcomes and pushing the envelope in cancer treatment methodologies.
Why Silexion Matters
In a landscape where new cancer therapies are urgently needed, Silexion's innovative approaches offer hope for patients with limited options. Their scientific expertise and persistent dedication to clinical research reflect their mission to improve lives through pioneering therapies. By participating in key investment summits and engaging with potential and existing investors, Silexion not only showcases its developments but also builds essential partnerships that could facilitate future breakthroughs.
Company Contacts
For additional information on the firm and its ongoing projects, stakeholders can reach out directly to:
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com
Frequently Asked Questions
What is the focus of Silexion Therapeutics?
Silexion is focused on developing RNA interference therapies for cancers driven by the KRAS oncogene.
When and where is Silexion presenting?
Silexion will present at the H.C. Wainwright Global Investment Conference from September 8-10.
What is the goal of their clinical trials?
The goal of their clinical trials is to develop effective treatments for solid tumor cancers, particularly those with KRAS mutations.
How can investors interact with Silexion's management team?
Investors can schedule one-on-one meetings with Silexion's management during the conference.
Who can I contact for more information?
For inquiries, you can contact Silexion Therapeutics' CFO, Ms. Mirit Horenshtein Hadar.
